HLX316 immunotherapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new experimental drug called HLX316 in people with advanced or metastatic (spread) solid cancers that have not responded to standard treatments. The drug is designed to help your immune system fight cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic solid cancer confirmed by biopsy that has failed at least one line of standard treatment, or you cannot tolerate or refused standard therapy
- Your cancer has at least one measurable tumor lesion that can be tracked on imaging scans
- You are in relatively good health (ECOG performance status 0 or 1) with an expected survival of at least 3 months
- You must wait at least 28 days after major surgery, chemotherapy, or immunotherapy before starting the study drug (shorter wait times for some other treatments)
- Your blood counts, liver, and kidney function meet minimum safety requirements on recent lab tests
- You must provide a tumor tissue sample (from prior biopsy or fresh biopsy) for testing of specific cancer markers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug (HLX48) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and how well it works.
This early-phase study tests a new drug called HLX37 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and how it works in the body.
This study tests a new pill called HLX97 for people with advanced breast, prostate, or lung cancer that has not responded to standard treatments. The goal is to find the safest dose and see if it can help slow or shrink the tumor.
This trial tests a new medication, HLX51, which may help the immune system fight cancer. It is for people with advanced solid tumors or lymphoma who have tried standard treatments without success or cannot receive them.
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.
Hear when a new Advanced/Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.